RT Journal Article
SR Electronic
T1 Prevalence of SARS-CoV-2 Antibodies from a one-year National Serosurveillance of Kenyan Blood Transfusion Donors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21260038
DO 10.1101/2021.07.06.21260038
A1 Uyoga, Sophie
A1 Adetifa, Ifedayo M.O.
A1 Otiende, Mark
A1 Gitonga, John N.
A1 Mugo, Daisy
A1 Nyagwange, James
A1 Karanja, Henry K.
A1 Tuju, James
A1 Makale, Johnstone
A1 Aman, Rashid
A1 Mwangangi, Mercy
A1 Amoth, Patrick
A1 Kasera, Kadondi
A1 Ng’ang’a, Wangari
A1 Kilonzo, Nduku
A1 Chege, Evelynn
A1 Yegon, Christine
A1 Odhiambo, Elizabeth
A1 Rotich, Thomas
A1 Orgut, Irene
A1 Kihara, Sammy
A1 Bottomley, Christian
A1 Kagucia, Eunice W.
A1 Gallagher, Katherine E.
A1 Etyang, Anthony
A1 Voller, Shirine
A1 Lambe, Teresa
A1 Wright, Daniel
A1 Barasa, Edwine
A1 Tsofa, Benjamin
A1 Mwangangi, Joseph
A1 Bejon, Philip
A1 Ochola-Oyier, Lynette I.
A1 Warimwe, George M.
A1 Agweyu, Ambrose
A1 Scott, J. Anthony G.
YR 2021
UL http://medrxiv.org/content/early/2021/07/07/2021.07.06.21260038.abstract
AB In tropical Africa, SARS-CoV-2 epidemiology is poorly described because of lack of access to testing and weak surveillance systems. Since April 2020, we followed SARS-CoV-2 seroprevalence in plasma samples across the Kenya National Blood Transfusion Service. We developed an IgG ELISA against full length spike protein. Validated in locally-observed, PCR-positive COVID-19 cases and in pre-pandemic sera, sensitivity was 92.7% and specificity was 99.0%. Using sera from 9,922 donors, we estimated national seroprevalence of SARS-CoV-2 antibodies at 4.3% in April-June 2020 and 9.1% in August-September 2020. Kenya’s second COVID-19 wave peaked in November 2020. Here we estimate national seroprevalence in early 2021.Between January 3 and March 15, 2021, we collected 3,062 samples from donors aged 16-64 years. Among 3,018 samples that met our study criteria, 1,333 were seropositive (crude seroprevalence 44.2%, 95% CI 42.4-46.0%). After Bayesian test-performance adjustment and population weighting to represent the national population distribution, the national estimate of seroprevalence was 48.5% (95% CI 45.2-52.1%). Seroprevalence varied little by age or sex but was higher in Nairobi (61.8%), the capital city, and lower in two rural regions.Almost half of Kenya’s adult donors had evidence of past SARS-CoV-2 infection by March 2021. Although high, the estimate is corroborated by other population-specific estimates in country. Between March and June, 2% of the population were vaccinated against COVID-19 and the country experienced a third epidemic wave. Natural infection is outpacing vaccine delivery substantially in Africa, and this reality needs to be considered as objectives of the vaccine programme are set.Competing Interest StatementRashid Aman, Mercy Mwangangi, Patrick Amoth, Kadondi Kasera are from the Ministry of Health in Kenya. Wangari Nganga is from the Presidential Policy and Strategy Unit of the Government of Kenya. All other authors declare no competing interests.Funding StatementThis project was funded by the Wellcome Trust (grant numbers 220991/Z/20/Z, 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547) and by the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039). Ambrose Agweyu is funded by a DFID/MRC/NIHR/Wellcome Trust Joint Global Health Trials Award (MR/R006083/1), J. Anthony G. Scott is funded by a Wellcome Trust Senior Research Fellowship (214320) and the NIHR Health Protection Research Unit in Immunisation, Ifedayo Adetifa is funded by the UK Medical Research Council through an African Research Leader Fellowship (MR/S005293/1) and by the NIHR-MPRU at UCL (grant 2268427 LSHTM). GMW is supported by a fellowship from the Oak Foundation. For the purpose of Open Access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. This paper has been published with the permission of the Director, Kenya Medical Research Institute. We thank all the blood donors for their contribution to the research. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The surveillance was approved by the Scientific and Ethics Review Unit of Kenya Medical Research Institute (Protocol SSC 3426).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data shown in the manuscript are available upon request from the corresponding author. De-identified data has been published on the Havard dataverse server https://doi.org/10.7910/DVN/3E1YSQ